FDMT Stock Fair Value Calculator – 4D Molecular Therapeutics Raises $120M Through Share Offering

Trending News ☀️

4D ($NASDAQ:FDMT) Molecular Therapeutics, a biopharmaceutical company, has recently announced a share offering of $120 million. The company is focused on leveraging its proprietary gene therapy and gene editing platform technologies to develop transformative treatments for serious and life-threatening genetic diseases. The company’s gene therapy platform is designed to deliver functional copies of therapeutic genes directly to patients, while its gene editing platform aims to precisely modify or replace single genes in the human genome. 4D Molecular Therapeutics has the potential to create groundbreaking treatments for genetic diseases, and this share offering could be a major step towards achieving that goal.

Stock Price

4D Molecular Therapeutics, a biotechnology and gene therapy company, made a big splash on Friday when it announced a successful share offering that raised $120 million. The stock opened at $16.1 and closed at $16.9, representing a 5.3% increase from the prior closing price of $16.1. This successful share offering puts 4D Molecular Therapeutics in an excellent position to continue research and development of its pioneering gene therapy treatments. The company is focused on developing novel gene therapies for rare genetic conditions, and the capital raised from this share offering provides a significant resource to support their efforts.

4D Molecular Therapeutics is continuing to make strides in the world of gene therapy, and the success of this share offering further demonstrates their potential as a leader in this industry. The additional capital will help them to build upon their current projects, allowing them to expand their research and development activities and bring new treatments to patients in need. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for FDMT. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for FDMT. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for FDMT. More…

Key Ratios Snapshot

Some of the financial key ratios for FDMT are shown below. More…

Analysis – FDMT Stock Fair Value Calculator

At GoodWhale, we have conducted an analysis of the wellbeing of 4D MOLECULAR THERAPEUTICS. Our proprietary Valuation Line has calculated the intrinsic value of 4D MOLECULAR THERAPEUTICS share to be around $17.8. Currently, the stock is being traded at $16.9, which is a fair price that is slightly undervalued by 5.2%. We believe that investing in 4D MOLECULAR THERAPEUTICS at this price would be an opportunity for investors to gain returns. More…

Peers

The company’s proprietary technology platform, Directed Evolution of Nucleic Acids (DENA), enables the directed evolution of highly specific nucleic acid therapeutics. 4D has a strategic collaboration with Genentech, a member of the Roche Group, for the development and commercialization of 4D-122, which is in Phase I clinical trials for the treatment of Duchenne muscular dystrophy (DMD). 4D’s main competitors are Freeline Therapeutics Holdings PLC, BioLine Rx Ltd, and Gossamer Bio Inc. All three companies are engaged in the discovery and development of therapeutics using cutting-edge technology platforms with the aim of bringing innovative treatments to patients with serious diseases.

– Freeline Therapeutics Holdings PLC ($NASDAQ:FRLN)

Freeline Therapeutics Holdings PLC is a clinical-stage biopharmaceutical company focused on developing therapeutics for the treatment of hemophilia and other bleeding disorders. The company has a market cap of $49.38 million and a return on equity of -1.18%. Freeline Therapeutics Holdings PLC is headquartered in London, the United Kingdom.

– BioLine Rx Ltd ($NASDAQ:BLRX)

BioLine Rx Ltd is a clinical-stage biopharmaceutical company, which engages in the identification, in-licensing, and development of therapeutics for the treatment of cancer and other therapeutic areas. The company was founded by Philip A. Serlin and Abraham B. Zlotnik on April 21, 2003 and is headquartered in Jerusalem, Israel.

– Gossamer Bio Inc ($NASDAQ:GOSS)

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. The company’s lead product candidate is GB001, an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Gossamer Bio Inc has a market cap of $990.28M as of 2022 and a Return on Equity of -1952.91%. The company focuses on the development of therapeutics in the areas of immunology, oncology, and inflammation. GB001, the company’s lead product candidate, is an anti-TNF-alpha antibody being developed for the treatment of inflammatory diseases. GB001 is currently in Phase 1 clinical trials.

Summary

4D Molecular Therapeutics recently raised $120 million through a share offering. This move provides the company with the necessary capital to fund their research and development efforts in the area of gene therapy. Since then, its stock price has been on an upward trend. This suggests that investors have been positive about the long-term prospects of the company. In terms of investing analysis, 4D Molecular Therapeutics appears to be a good option with a long-term growth potential. The company is at the forefront of gene therapy and is well positioned to benefit from advances in this field.

Additionally, the recent share offering has provided the company with necessary capital to invest in its research and development initiatives. The company’s future success is dependent on these initiatives, and investors should watch how they evolve in the coming years. In conclusion, 4D Molecular Therapeutics appears to be a promising investment opportunity for those looking for long-term growth potential.